1336 related articles for article (PubMed ID: 28483959)
1. Gepotidacin (GSK2140944)
Flamm RK; Farrell DJ; Rhomberg PR; Scangarella-Oman NE; Sader HS
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483959
[TBL] [Abstract][Full Text] [Related]
2.
Farrell DJ; Sader HS; Rhomberg PR; Scangarella-Oman NE; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069643
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens.
Biedenbach DJ; Bouchillon SK; Hackel M; Miller LA; Scangarella-Oman NE; Jakielaszek C; Sahm DF
Antimicrob Agents Chemother; 2016 Jan; 60(3):1918-23. PubMed ID: 26729499
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
[TBL] [Abstract][Full Text] [Related]
5.
Scangarella-Oman NE; Ingraham KA; Tiffany CA; Tomsho L; Van Horn SF; Mayhew DN; Perry CR; Ashton TC; Dumont EF; Huang J; Brown JR; Miller LA
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818823
[TBL] [Abstract][Full Text] [Related]
6. Analysis of MIC and Disk Diffusion Testing Variables for Gepotidacin and Comparator Agents against Select Bacterial Pathogens.
Koeth LM; DiFranco-Fisher JM; Scangarella-Oman NE; Miller LA
J Clin Microbiol; 2017 Jun; 55(6):1767-1777. PubMed ID: 28330893
[TBL] [Abstract][Full Text] [Related]
7.
Jensen JS; Nørgaard C; Scangarella-Oman N; Unemo M
Emerg Microbes Infect; 2020 Dec; 9(1):1388-1392. PubMed ID: 32552547
[No Abstract] [Full Text] [Related]
8. Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against Staphylococcus aureus Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells.
Peyrusson F; Tulkens PM; Van Bambeke F
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358297
[TBL] [Abstract][Full Text] [Related]
9. Comparison of minimum inhibitory concentration results for gepotidacin obtained using agar dilution and broth microdilution methods.
Arends SJR; Canino MA; Mendes R; Scangarella-Oman NE; Flamm RK
Diagn Microbiol Infect Dis; 2020 Oct; 98(2):115107. PubMed ID: 32795850
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.
Karlowsky JA; Adam HJ; Decorby MR; Lagacé-Wiens PR; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2011 Jun; 55(6):2837-46. PubMed ID: 21402844
[TBL] [Abstract][Full Text] [Related]
11.
Hackel MA; Karlowsky JA; Canino MA; Sahm DF; Scangarella-Oman NE
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0216521. PubMed ID: 34930028
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae.
Licata L; Smith CE; Goldschmidt RM; Barrett JF; Frosco M
Antimicrob Agents Chemother; 1997 May; 41(5):950-5. PubMed ID: 9145850
[TBL] [Abstract][Full Text] [Related]
13. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
Biedenbach DJ; Beach ML; Jones RN
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):173-7. PubMed ID: 11576790
[TBL] [Abstract][Full Text] [Related]
14. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
15. Analysis of antimicrobial susceptibility testing methods and variables and in vitro activity of gepotidacin against urogenital Neisseria gonorrhoeae in men.
Scangarella-Oman NE; Dixon P; Koeth LM; DiFranco-Fisher J; Miller LA
Diagn Microbiol Infect Dis; 2021 Dec; 101(4):115484. PubMed ID: 34419740
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
[TBL] [Abstract][Full Text] [Related]
17. Bactericidal kinetics and postantibiotic effect of sparfloxacin against selected species of respiratory pathogens.
Speciale A; Blandino G; Nicolosi VM; Siracusa V; Caccamo F
J Chemother; 1995 Dec; 7(6):530-4. PubMed ID: 8667038
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
Pillar CM; Aranza MK; Shah D; Sahm DF
J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
